Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sanofi Oncology Strategy: A New Lease On Cancer R&D

Executive Summary

The company is rebooting after several late-stage setbacks in cancer R&D, relying on a collaboration with Regeneron to vault it into the field of immuno-oncology.

Advertisement

Related Content

The Bell Tolls For Fedratinib In A Setback For Sanofi’s Oncology Portfolio
Role Of Cost And Evidence In Value-Based Purchasing Highlighted By Zaltrap Price Adjustment

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register